KisoJi Biotechnology
PrivateLast Round
Series B
Dec 2, 2024
Total Funding Raised
$41M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
KisoJi Biotechnology operates in Healthcare & Life Sciences and is based in Montreal. Its latest recorded funding round was a Series B round in December 2024.
KisoJi Biotechnology is a biotechnology company that develops multi-specific antibody therapeutics for oncology and inflammatory diseases using a proprietary AI-enabled discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
KisoJi Biotechnology Comparables
Compare KisoJi Biotechnology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BigHat Biosciences | 82% | |
| Alloy Therapeutics | 81% | |
| Leveragen, Inc. | 80% |
For institutional investors. Book with your work email.
KisoJi Biotechnology Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
KisoJi Biotechnology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Investissement Québec | Series B |
| Fonds de solidarité FTQ | Series B |
| Remiges Ventures | Series A Extension, Series B |
| BDC Capital | Series A Extension |
| Lumira Ventures | Series B |
| adMare BioInnovations | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 2, 2026
Open roles increased to 35, 2.5x the trailing average.
- Aug 29, 2026
Grew 31% QoQ, from 16 to 21 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesAug 17, 2026
On Aug 17th '26, KisoJi Biotechnology Inc. and Cancer Research UK launch a Phase I/IIa trial evaluating the safety and effectiveness of KJ-103, a naked anti-TROP2 antibody, in selected TROP2-expressing solid tumours.
- is_developingAug 14, 2026
KisoJi Biotechnology Inc. is developing KJ-103, a naked anti-TROP2 antibody, in collaboration with Cancer Research UK's Centre for Drug Development and Cancer Research Horizons; the Phase 1/2a trial evaluates its safety, dose levels and preliminary efficacy in selected solid tumours, with the first patient treated in the United Kingdom in Aug '26.
For institutional investors. Book with your work email.
KisoJi Biotechnology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about KisoJi Biotechnology's valuation, stock price, and market status.
Is KisoJi Biotechnology a public or private company?
KisoJi Biotechnology is a private company.
What is the current stock price of KisoJi Biotechnology?
KisoJi Biotechnology is a private company, so its shares have no public market price. Caplight tracks KisoJi Biotechnology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is KisoJi Biotechnology worth (valuation)?
Valuation information for KisoJi Biotechnology is not publicly available.
Can I buy KisoJi Biotechnology stock?
KisoJi Biotechnology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was KisoJi Biotechnology's last funding round?
KisoJi Biotechnology's most recent funding round was Series B on December 2, 2024.
Who are the main investors in KisoJi Biotechnology?
Key investors in KisoJi Biotechnology include Investissement Québec, Lumira Ventures.
Will KisoJi Biotechnology IPO soon?
No public IPO plans have been announced for KisoJi Biotechnology.
How can I track KisoJi Biotechnology secondary market activity?
Caplight tracks bids, offers, and trades in KisoJi Biotechnology's shares on secondary markets.